Company Filing History:
Years Active: 2021
Title: Jens Wuerthner: Innovator in Cancer Treatment
Introduction
Jens Wuerthner is a notable inventor based in Steinen, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of two patents, Wuerthner is recognized for his work in developing therapies that target critical interactions in cancer biology.
Latest Patents
Wuerthner's latest patents include groundbreaking inventions aimed at improving cancer treatment. One of his patents focuses on "Dose and regimen for HDM2-p53 interaction inhibitors." This invention relates to the use of HDM2-p53 interaction inhibitors for cancer treatment, specifically through a high dose intermittent dosing regimen. The patent details the HDM2-p53 interaction inhibitor HDM20I and outlines a dosing regimen for a four-week cycle.
Another significant patent is titled "GDF-15 as a haematological toxicity biomarker." This disclosure pertains to the use of GDF-15 as a safety biomarker for assessing the toxicological effects of Mdm2 inhibitors. It includes methods for determining the likelihood of developing thrombocytopenia in patients undergoing treatment with Mdm2 inhibitors, as well as kits designed to predict and manage these risks in cancer patients.
Career Highlights
Wuerthner is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions for cancer treatment, contributing to the advancement of medical science and patient care.
Collaborations
Throughout his career, Wuerthner has collaborated with esteemed colleagues, including Nelson Guerreiro and Christophe Meille. These partnerships have fostered a collaborative environment that enhances the development of effective cancer therapies.
Conclusion
Jens Wuerthner's contributions to cancer treatment through his patents and collaborations highlight his role as an influential inventor in the medical field. His innovative approaches continue to pave the way for advancements in cancer therapy and patient safety.